Honing in on one family that may hold the key to unlocking some of the secrets of Alzheimer's, Genentech Inc. has joined an international collaboration in a unique clinical trial that will open the door to shared research in hopes of finding a way to prevent the disease. Read More
Oncomed Pharmaceuticals Inc. filed an initial public offering (IPO), hoping for about $115 million to support its antibody therapies targeted at cancer stem cells (CSCs). Read More
Four years after its launch and two years after the company quietly secured a $27 million Series A round, Ra Pharmaceuticals Inc. revealed hereditary angioedema (HAE) as the initial target for its cyclomimetics – peptide-like molecules that incorporate non-natural amino acids. Read More
• Rainbow Biosciences LLC, of Nokomis, Fla., the biotech subsidiary of Rainbow Coral Corp (RBCC)., said it is discussing a potential joint venture with Amarantus BioSciences Inc., of Sunnyvale, Calif., which owns the rights to a therapeutic protein, MANF, for Parkinson's disease. Read More
• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said its SynCon avian influenza vaccine generated protective hemagglutination inhibition titers against six different unmatched strains of H5N1 in a Phase I trial. The vaccine generated an HAI titer of 1:40 or higher against at least one of the six tested strains in eight of 17 (47 percent) immunized subjects; 12 of 17 (71 percent) vaccines generated an HAI titer of 1:20 or higher, indicating a positive vaccine response, against at least one H5N1 strain. Read More
• Pfizer Inc., of New York, said the Phase III INTORSECT study testing Torisel (temsirolimus) in patients with advanced renal cell carcinoma whose disease had progressed on or after Sutent (sunitinib malate) therapy did not meet the primary endpoint of prolonging progression-free survival (PFS) when compared to Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG). Read More
